Doxazosin treatment and peroxidation of low-density lipoprotein among male hypertensive subjects: In vitro and ex vivo studies

Biochemical Pharmacology

Volumn 58, Issue 1, 1999, Pages 183-191

  Brude, Ingeborg R ^a   Drevon, Christian A ^a   Viken, Kjersti ^a   Arnstad, Jon E ^a   Valnes, Kolbjørn N ^a   Nenseter, Marit S ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Doxazosin; Human mononuclear cells; Hypertensive; LDL; Lipid peroxidation; Oxidation

Indexed keywords

6' HYDROXYDOXAZOSIN; 7' HYDROXYDOXAZOSIN; ANTIHYPERTENSIVE AGENT; DOXAZOSIN; DRUG METABOLITE; LOW DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ELECTROPHORETIC MOBILITY; ESSENTIAL HYPERTENSION; HUMAN; HUMAN CELL; HYPERTENSION; IN VITRO STUDY; LIPID OXIDATION; LIPID PEROXIDATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCAVENGING SYSTEM;

ADULT; AGED; AMIDINES; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; BEPRIDIL; COPPER; DOXAZOSIN; FREE RADICAL SCAVENGERS; HUMANS; HYPERTENSION; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDANTS; PICRATES;

EID: 0033168583     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00057-X     Document Type: Article

References (29)

1. Collins R., Peto R., MacMahon S., Herbert P., Fiebach N.H., Eberlein K.A., Godwin J., Qizilibash N., Taylor J.O., Hennekens C.H. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reduction in blood pressure Overview of randomised drug trials in their epidemiological context . Lancet. 335:1990;827-838.
2. Keidar S., Kaplan M., Shapira C., Brook J.G., Aviram M. Low-density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages: A possible role for angiotensin II. Atherosclerosis. 107:1994;71-84.
3. Breugnot C., Maziére C., Auclair M., Mora L., Ronveaux M.F., Salmon S., Santus R., Morliere P., Lenaers A., Maziere J.C. Calcium antagonists prevent monocyte and endothelial cell-induced modification of low-density lipoproteins. Free Radic Res Commun. 15:1991;91-100.
4. Maziere C., Auclair M., Maziere J.C. Lipophilic beta-blockers inhibit monocyte and endothelial cell-mediated modification of low-density lipoproteins. Biochim Biophys Acta. 1126:1992;314-318.
5. Babamoto K.S., Hirokawa W.T. Doxazosin: A new alpha 1-adrenergic antagonist. Clin Pharmacol. 11:1992;415-427.
6. Karge W.H. III, Kowala E.J., Weiner E.J., Nicolosi R.J. Serum lipids, lipoproteins, hemodynamics, and hemostasis in doxazosin-treated monkeys. Cardiovasc Pharmacol. 13:(Suppl 2):1989;S25-S30.
7. Foxall T.L., Shwaery G.T., Stucchi A.F., Nicolosi R.J., Wong S.S. Dose-related effects of doxazosin on plasma lipids and aortic fatty streak formation in the hypercholesterolemic hamster model. Am J Pathol. 140:1992;1357-1363.
8. Swindell A.C., Krupp M.N., Twomey T.M., Reynolds J.A., Chichester C.O. Effects of doxazosin on atherosclerosis in cholesterol-fed rabbits. Atherosclerosis. 99:1993;195-206.
9. Chait A., Gilmore M., Kawamura M. Inhibition of low-density lipoprotein oxidation in vitro by the 6- and 7-hydroxy-metabolites of doxazosin, an alpha 1-adrenergic antihypertensive agent. Am J Hypertens. 7:1994;159-167.
10. Havel R.J., Eder H.A., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 34:1955;1345-1352.
11. Nenseter M.S., Halvorsen B., Rosvold O., Rustan A.C., Drevon C.A. Paracetamol inhibits copper ion-induced, azo compound-initiated, and mononuclear cell-mediated oxidative modification of LDL. Arterioscler Thromb Vasc Biol. 15:1995;1338-1344.
12. Brude I.R., Drevon C.A., Hjermann I., Seljeflot I., Lund-Katz S., Saarem K., Sandstad B., Solvoll K., Halvorsen B., Arnesen H., Nenseter M.S. Peroxidation of LDL from combined-hyperlipidemic male smokers supplied with ω-3 fatty acids and antioxidants. Arterioscler Thromb Vasc Biol. 17:1997;2576-2588.
13. Esterbauer H., Striegl G., Puhl H., Rotheneder M. Continuous monitoring of in vitro oxidation of human low-density lipoprotein. Free Radic Res Commun. 6:1989;67-75.
14. Buege J.A., Aust S.D. Microsomal lipid peroxidation. Methods Enzymol. 52:1978;302-310.
15. Solvoll K., Lund-Larsen K., Søyland E., Sandstad B., Drevon C.A. A quantitative food frequency questionnaire evaluated in a group of dermatologic outpatients. Scand J Nutr. 37:1993;150-155.
16. Rumsey S.C., Galeano N.F., Arad Y., Deckelbaum R.J. Cryopreservation with sucrose maintains normal physical and biological properties of human plasma low-density lipoproteins. J Lipid Res. 33:1992;1551-1561.
17. Stocker R., Bowry V.W., Frei B. Ubiquinol-10 protects human low-density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol. Proc Natl Acad Sci USA. 88:1991;1646-1650.
18. Frei B., Gaziano J.M. Content of antioxidants, preformed lipid hydroperoxides, and cholesterol as predictors of the susceptibility of human LDL to metal ion-dependent and -independent oxidation. J Lipid Res. 34:1993;2135-2145.
19. Berke MS and Busch D, Method validation report: Validation of an assay for the measurement of doxazosin and three metabolites in human plasma by high-performance liquid chromatography. by Hazleton Wisconsin, Inc. for Pfizer, Inc. New York, Madison, Wisconsin; 1993.
20. Miller N.J., Rice-Evans C., Davies M.J., Gopinathan V., Milner A. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci (Colch). 84:1993;407-412.
21. Ohishi N., Ohkawa H., Miike A., Tatano T., Yagi K. A new assay method for lipid peroxides using a methylene blue derivative. Biochem Int. 10:1985;205-211.
22. Noble R.P. Electrophoretic separation of plasma lipoproteins in agarose gel. J Lipid Res. 9:1968;693-700.
23. Altman D.G. Practical Statistics for Medical Research. 1995;Chapman & Hall, London.
24. Packer J.E., Slater T.F., Willson R.L. Direct observation of a free radical interaction between vitamin E and vitamin C. Nature. 278:1979;737-738.
25. Jialal I., Vega G.L., Grundy S.M. Physiologic levels of ascorbate inhibit the oxidative modification of low-density lipoprotein. Atherosclerosis. 82:1990;185-191.
26. Frei B. Ascorbic acid protects lipids in human plasma and low-density lipoprotein against oxidative damage. Am J Clin Nutr. 54:1991;1113S-1118S.
27. Jialal I., Grundy S.M. Preservation of the endogenous antioxidants in low-density lipoprotein by ascorbate but not probucol during oxidative modification. J Clin Invest. 87:1991;597-601.
28. Fuller C.J., Grundy S.M., Norkus E.P., Jialal I. Effect of ascorbate supplementation on low-density lipoprotein oxidation in smokers. Atherosclerosis. 119:1996;139-150.
29. Elliott H.L., Meredith P.A., Reid J.L. Pharmacokinetic overview of doxazosin. Am J Cardiol. 59:1987;78G-81G.